Key result
Pharmaceutical modulation of platelet glycoprotein VI and its downstream signaling pathways is a promising antiplatelet strategy for treating thrombotic diseases without significant bleeding risk.
Why the study?
Antiplatelet therapy aims to prevent thrombotic events without impairing hemostasis, making GPVI modulation a promising target for effective and safe treatment of thrombotic diseases without significant bleeding risk.
Design
Review
Authors
Loading...
GPVI inhibition merits clinical evaluation for safer antithrombotic effects; leaves open confirmation in randomized trials.
Inhibition of platelet glycoprotein GPVI represents a promising antiplatelet strategy that may prevent thrombosis without significantly increasing the risk of bleeding.
Eduardo Fuentes (2022) conducted a review in Thrombotic diseases. Modulation of Glycoprotein VI and its downstream signaling pathways was evaluated. Pharmaceutical modulation of platelet glycoprotein VI and its downstream signaling pathways is a promising antiplatelet strategy for treating thrombotic diseases without significant bleeding risk.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: